Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Poor pregnancy outcome after octreotide treatment during pregnancy for familial hyperinsulinemic hypoglycemia: a case report

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Jolt accentuation of headache: can this maneuver rule out acute meningitis?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prevalence and significance of Mycoplasma genitalium in women living with HIV in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effect of motivational interviewing on gestational weight gain and fetal growth in pregnant women with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Increased leptin, decreased adiponectin and FGF21 concentrations in adolescent offspring of women with gestational diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. White coat hypertension in early pregnancy in women with pre-existing diabetes: prevalence and pregnancy outcomes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Migration, body mass index and gestational diabetes mellitus among women in Denmark 2004-2015: a register-based study

    Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

View graph of relations

BACKGROUND: Late familial hyperinsulinemic hypoglycemia is characterized by recurrent episodes of hypoglycemia and an inappropriate insulinemic response. Treatment with octreotide (somatostatin analogue) reduces the prevalence of clinical significant hypoglycemia and might be beneficial during pregnancy. To our knowledge this is the first report of a woman with late familial hyperinsulinemic hypoglycemia experiencing pregnancies with and without octreotide treatment.

CASE PRESENTATION: A 35-year-old Caucasian woman known to suffer from late familial hyperinsulinemic hypoglycemia due to a well-known mutation in the insulin receptor gene has been pregnant 6 times. The patient was treated with injections of Sandostatin LAR(R) (octreotide) during the first four pregnancies. Her first pregnancy in 1999 was unknown until approximately 25th gestational weeks with fatal intrauterine growth retardation. The following two pregnancies were terminated on parental request after a chorion villus biopsy revealed the mutation causing late familial hyperinsulinemic hypoglycemia. During the fourth pregnancy, in which the fetus also had the mutation, serial ultrasound examinations showed a small fetus with appropriate growth. At birth the girl was small for gestational age. She was admitted to the neonatal special care unit due to low blood glucose and intravenous glucose and early feeding was initiated. One day old, her condition deteriorated with signs of an abdominal catastrophe indicating necrotizing enterocolitis. After two laparotomies - both confirming necrotizing enterocolitis - the child died 8 days after birth.In the following two pregnancies Sandostatin LAR(R) was stopped before pregnancy and the patient was treated only with diet restriction and intensive glucose monitoring. Both pregnancies ended successfully. One child carried the mutation and was small for gestational age at birth while the other child did not carry the mutation and had normal birth weight.

CONCLUSION: In a woman with late familial hyperinsulinemic hypoglycemia octreotide was given during the first four pregnancies resulting in 2 cases of early termination of pregnancy on parental request and 2 cases of inappropriate fetal growth and unviable outcome. The following two pregnancies treated with diet only had a successful outcome.

Original languageEnglish
JournalBMC Research Notes
Volume7
Issue number1
Pages (from-to)804
ISSN1756-0500
DOIs
Publication statusPublished - 17 Nov 2014

ID: 44699724